Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin9623 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49054 | 19906067 | Cancer Sci | Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. | 2009 | Details |
| A49066 | 19538246 | Diabet Med | Insulin resistance and endothelial dysfunction in type 2 diabetic patients with non-alcoholic steatohepatitis. | 2009 | Details |
| A49079 | 18793162 | Biochem Soc Trans | NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? | 2008 | Details |
| A49086 | 22967918 | Endocrinol Nutr | Hepatic involvement in a teenager with type 1 diabetes and poor metabolic control. | 2008 | Details |
| A49090 | 18400637 | Anadolu Kardiyol Derg | [Global confusion on the diagnostic criteria for metabolic syndrome: what is the point that guidelines can not agree?]. | 2008 | Details |
| A49094 | 18290780 | Liver Int | Previous practice of high-intensity sports as a risk factor for non-alcoholic steatohepatitis. | 2008 | Details |
| A49106 | 17435339 | Nihon Yakurigaku Zasshi | [Candidate drugs for non-alcoholic steatohepatitis (NASH)]. | 2007 | Details |
| A49117 | 17058987 | Rev Gastroenterol Mex | [Ghrelin: beyond hunger regulation]. | 2006 | Details |
| A49125 | 16622296 | Endocrine | Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. | 2006 | Details |
| A49126 | 16610061 | World J Gastroenterol | Cryptogenic cirrhosis in the region where obesity is not prevalent. | 2006 | Details |
| A49134 | 16499208 | Nihon Naika Gakkai Zasshi | [Non-alcoholic steatohepatitis. 3. Oxidative stress and NASH]. | 2006 | Details |
| A49135 | 16499207 | Nihon Naika Gakkai Zasshi | [Non-alcoholic steatohepatitis (NASH). 2. Insulin resistance and NASH]. | 2006 | Details |
| A49147 | 16225471 | Aliment Pharmacol Ther | Review article: steatosis, the metabolic syndrome and cancer. | 2005 | Details |
| A49153 | 16165706 | Scand J Gastroenterol | Invasive and non-invasive investigations for non-alcoholic steatohepatitis: the benefit of histology. | 2005 | Details |
| A49154 | 16137475 | Gastroenterol Hepatol | [Etiopathogenesis of non-alcoholic steatohepatitis]. | 2005 | Details |
| A49156 | 16097995 | Aliment Pharmacol Ther | Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. | 2005 | Details |
| A49165 | 15698360 | Med J Aust | 3. Management and prevention of obesity and its complications in children and adolescents. | 2005 | Details |
| A49169 | 15641470 | Gac Med Mex | [Obesity and steatohepatitis. Histologic aspects]. | 2005 | Details |
| A49175 | 15489566 | Eur J Gastroenterol Hepatol | Mitochondrial injury in steatohepatitis. | 2004 | Details |
| A49184 | 15094675 | Gastroenterol Clin Biol | [Improving insulin resistance: certain progress in the management of patients with non-alcoholic steatohepatitis...but the story continues]. | 2004 | Details |
| A49185 | 15040152 | Vnitr Lek | [The metabolic syndrome]. | 2003 | Details |
| A49187 | 14987322 | Aliment Pharmacol Ther | Metformin in the treatment of patients with non-alcoholic steatohepatitis. | 2004 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49203 | 35830037 | Arq Gastroenterol | OBSTRUCTIVE SLEEP APNEA SYNDROME RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH OBESITY AND PRESENCE OF NASH. | 2022 | Details |
| A49208 | 35822119 | JGH Open | Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. | 2022 | Details |
| A49209 | 35822025 | Front Aging | INDY-From Flies to Worms, Mice, Rats, Non-Human Primates, and Humans. | 2021 | Details |
| A49210 | 35821558 | Curr Diab Rep | Lipodystrophy for the Diabetologist-What to Look For. | 2022 | Details |
| A49214 | 35817677 | J Diabetes Complications | Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. | 2022 | Details |
| A49216 | 35820743 | BMJ Open | Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. | 2022 | Details |
| A49220 | 35818251 | Cell Mol Biol (Noisy-le-grand) | Effects of endoplasmic reticulum stress, liver function, insulin resistance and vascular endothelial function in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49223 | 35817047 | Exp Clin Endocrinol Diabetes | Comorbidities in Mild Autonomous Cortisol Secretion - A Clinical Review of Literature. | 2022 | Details |
| A49226 | 35816139 | J Sports Med Phys Fitness | The effect of aerobic exercise on metabolic parameters of patients with non-alcoholic fatty liver disease: systematic review and meta-analysis. | 2022 | Details |
| A49228 | 35814521 | J Clin Exp Hepatol | Quantitative Ultrasound Assessment of Hepatic Steatosis. | 2022 | Details |
| A49243 | 35811725 | Front Cardiovasc Med | Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) - Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease. | 2022 | Details |
| A49262 | 35806934 | J Clin Med | The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. | 2022 | Details |
| A49271 | 35806010 | Int J Mol Sci | MAFLD and CKD: An Updated Narrative Review. | 2022 | Details |
| A49288 | 35799081 | Pharm Res | Lipocalin-Type Prostaglandin D2 Synthase Protein- A Central Player in Metabolism. | 2022 | Details |
| A49309 | 35792732 | Biomarkers | Chemical compositions of Commiphora opobalsamum stem bark to alleviate liver complications in streptozotocin-induced diabetes in rats: Role of oxidative stress and DNA damage. | 2022 | Details |
| A49325 | 35788089 | Chin Med J (Engl) | Bile acids and sphingolipids in non-alcoholic fatty liver disease. | 2022 | Details |
| A49332 | 35785498 | Phytother Res | Effects of licorice root supplementation on liver enzymes, hepatic steatosis, metabolic and oxidative stress parameters in women with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. | 2022 | Details |
| A49336 | 35784568 | Front Endocrinol (Lausanne) | Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children - From Disease Pathogenesis to Complications. | 2022 | Details |
| A49337 | 35784557 | Front Endocrinol (Lausanne) | Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis. | 2022 | Details |
| A49338 | 35784533 | Front Endocrinol (Lausanne) | Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A49340 | 35783879 | Cureus | Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. | 2022 | Details |
| A49345 | 35782916 | Front Nutr | Metabolic and Microbiome Alterations Following the Enrichment of a High-Fat Diet With High Oleic Acid Peanuts Versus the Traditional Peanuts Cultivar in Mice. | 2022 | Details |
| A49346 | 35782914 | Front Nutr | The Human Milk Oligosaccharide 2'-Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr-/-.Leiden Mice. | 2022 | Details |
| A49348 | 35782337 | Gastroenterol Res Pract | Research Progress on the Mechanism of Acupuncture Treatment for Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49352 | 35780841 | Life Sci | Ellagic acid ameliorates high fructose-induced hyperuricemia and non-alcoholic fatty liver in Wistar rats: Focusing on the role of C1q/tumor necrosis factor-related protein-3 and ATP citrate lyase. | 2022 | Details |
| A49353 | 35780715 | Growth Horm IGF Res | Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | 2022 | Details |
| A49358 | 35779256 | J Clin Endocrinol Metab | The GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity. | 2022 | Details |
| A49359 | 35779187 | Cell Stress Chaperones | Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats. | 2022 | Details |
| A49360 | 35778847 | Lipids | Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. | 2022 | Details |
| A49361 | 35778734 | Cardiovasc Diabetol | TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. | 2022 | Details |
| A49366 | 35777449 | Biochem Pharmacol | Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. | 2022 | Details |
| A49369 | 35773644 | BMC Gastroenterol | Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. | 2022 | Details |
| A49384 | 35767969 | Ann Nutr Metab | Reversal of diabesity: Normalization of insulin release curve in association with reversal of non-alcoholic fatty liver disease. | 2022 | Details |
| A49387 | 35766833 | Compr Physiol | Paying the Iron Price: Liver Iron Homeostasis and Metabolic Disease. | 2022 | Details |
| A49392 | 35765700 | Hepatol Commun | Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. | 2022 | Details |
| A49394 | 35765391 | Cureus | The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49395 | 35765060 | Cell Biosci | Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. | 2022 | Details |
| A49399 | 35764198 | J Ethnopharmacol | Exploring therapeutic mechanisms of San-Huang-Tang in nonalcoholic fatty liver disease through network pharmacology and experimental validation. | 2022 | Details |
| A49403 | 35762159 | Curr Opin Clin Nutr Metab Care | Intrahepatic triglyceride content: influence of metabolic and genetics drivers. | 2022 | Details |
| A49404 | 35761888 | Diabetes Metab Syndr Obes | Risk Factors for Nonalcoholic Fatty Liver Disease in Postmenopausal Women with Type 2 Diabetes Mellitus and the Correlation with Bone Mineral Density at Different Locations. | 2022 | Details |
| A49409 | 35760093 | Life Sci | The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions. | 2022 | Details |
| A49418 | 35757255 | Front Nutr | Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management. | 2022 | Details |
| A49422 | 35757117 | Front Pediatr | Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. | 2022 | Details |
| A49423 | 35755273 | Acta Pharm Sin B | Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy-lysosomal pathway. | 2021 | Details |
| A49442 | 35748302 | J Gastroenterol Hepatol | Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis. | 2022 | Details |
| A49460 | 35744822 | Molecules | Neuroendocrine-Immune Regulatory Network of Eucommia ulmoides Oliver. | 2022 | Details |
| A49464 | 35744024 | Medicina (Kaunas) | An Update on the Chemokine System in the Development of NAFLD. | 2022 | Details |
| A49468 | 35743545 | J Clin Med | Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49469 | 35743358 | J Clin Med | When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. | 2022 | Details |
| A49471 | 35743232 | Int J Mol Sci | SIRT2 Deficiency Exacerbates Hepatic Steatosis via a Putative Role of the ER Stress Pathway. | 2022 | Details |
| A49478 | 35740464 | Biomedicines | The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. | 2022 | Details |
| A49479 | 35740337 | Biomedicines | Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology. | 2022 | Details |
| A49484 | 35740245 | Biomedicines | Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach. | 2022 | Details |
| A49486 | 35740032 | Antioxidants (Basel) | NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. | 2022 | Details |
| A49493 | 35738176 | Biomed Pharmacother | Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment. | 2022 | Details |
| A49498 | 35736186 | Mar Drugs | Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49517 | 35728960 | Cas Lek Cesk | Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis. | 2022 | Details |
| A49520 | 35728768 | Free Radic Biol Med | Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2. | 2022 | Details |
| A49524 | 35726797 | Food Funct | Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. | 2022 | Details |
| A49527 | 35726152 | Endocrinol Metab (Seoul) | The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018. | 2022 | Details |
| A49530 | 35724509 | Biomed Pharmacother | Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. | 2022 | Details |
| A49534 | 35723052 | Food Funct | Coffee peel extracts ameliorate non-alcoholic fatty liver disease via a fibroblast growth factor 21-adiponectin signaling pathway. | 2022 | Details |
| A49540 | 35721171 | Front Pharmacol | Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification. | 2022 | Details |
| A49543 | 35720958 | 3 Biotech | Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction. | 2022 | Details |
| A49550 | 35718058 | Am J Pathol | Dysregulation of Lipid and Glucose Homeostasis in Hepatocyte-Specific SLC25A34 Knockout Mice. | 2022 | Details |
| A49558 | 35714570 | Biochem Biophys Res Commun | TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells. | 2022 | Details |
| A49559 | 35713877 | Diabetes | Hyperinsulinemia is Highly Associated with Markers of Hepatocytic Senescence in Two Independent Cohorts. | 2022 | Details |
| A49561 | 35713614 | Lab Med | Association of rs5742612 Polymorphism in the Promoter Region of IGF1 Gene with Nonalcoholic Fatty Liver Disease: A Case-Control Study. | 2022 | Details |
| A49562 | 35713152 | J Cell Mol Med | Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway. | 2022 | Details |
| A49568 | 35710164 | Scand J Gastroenterol | The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial. | 2022 | Details |
| A49577 | 35708630 | J Med Food | Nil-Surin Rice Bran Hydrolysates Improve Lipid Metabolism and Hepatic Steatosis by Regulating Secretion of Adipokines and Expression of Lipid-Metabolism Genes. | 2022 | Details |
| A49587 | 35702836 | J Assoc Physicians India | Interrelation of the Risk Factors of NAFLD at various Stages of Progression of the glycemic Status on long-term Follow-up. | 2022 | Details |
| A49588 | 35702577 | Intractable Rare Dis Res | Diagnosing Alström syndrome in a patient followed up with syndromic obesity for years. | 2022 | Details |
| A49606 | 35693397 | Hepatobiliary Surg Nutr | Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients. | 2022 | Details |
| A49629 | 35685554 | Int J Clin Pract | The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes. | 2022 | Details |
| A49632 | 35684158 | Nutrients | 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway. | 2022 | Details |
| A49635 | 35684022 | Nutrients | Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. | 2022 | Details |